NEW YORK (GenomeWeb News) – Third Wave Technologies said yesterday that it has field a shelf registration with the US Securities and Exchange Commission allowing it to sell up to $100 million in securities.
The molecular diagnostics company said it may sell an undetermined number of debt securities or common stock, which includes the rights to purchase preferred stock, and that all of these may be issued by exercising warrants.
Third Wave plans to use the proceeds of the sale of the securities, which have not been priced, for working capital, and for corporate purposes that could include R&D spending, capital expenses, and for acquisitions of companies, products, or technologies.
The Madison, Wis.-based company said it currently has no plans for any specific acquisitions, but that “opportunities may exist” for expansion through acquisition, alliances, or through other deals.